Genenta Science S.p.A. - American Depositary Shares (GNTA)
0.9499
-0.0102 (-1.06%)
NASDAQ · Last Trade: Feb 27th, 12:40 PM EST
Detailed Quote
Previous Close
0.9601
Open
0.9865
Bid
0.9499
Ask
0.9750
Day's Range
0.9499 - 0.9865
52 Week Range
0.7050 - 10.00
Volume
29,652
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
2,817,399
Chart
About Genenta Science S.p.A. - American Depositary Shares (GNTA)
Genenta Science S.p.A. is a biotechnology company focused on developing innovative gene therapies for oncology. The company specializes in harnessing the power of its proprietary, engineered cell-based therapies to combat various forms of cancer. By using genetic engineering techniques, Genenta aims to create treatments that can enable the immune system to recognize and fight tumors effectively. Their research and development efforts are centered on creating safe and effective therapeutic options for patients facing significant health challenges due to cancer, with the goal of transforming the landscape of cancer treatment through cutting-edge science and technology. Read More
MILAN and NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- In response to evolving market dynamics and strategic opportunities, Genenta Science S.p.A (Nasdaq: GNTA) is embarking on a strategic transformation to evolve into a next-generation strategic industrial consolidator focused on acquiring privately held businesses operating in national-security regulated sectors contemplated by the Italian Golden Power1 legislation. The Company intends to target majority ownership in companies with established operating profitability, typically generating up to approximately €5 million in EBITDA2. In this context, Genenta plans to adopt the new corporate name of Saentra Forge S.p.A. with a new Nasdaq ticker symbol of SAEN3.
MILAN and NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a clinical-stage gene-therapy company developing hematopoietic stem-cell-based immunotherapies for solid tumors, provides an update regarding the ownership position of its Chief Executive Officer and Co-Founder, Pierluigi Paracchi.
The company said that 25 patients have been treated with Temferon as of November 21, and 44% of glioblastoma multiforme patients have reached 18-month survival.
Synergy CHC Corp. (NASDAQ: SNYR), a leading consumer health and wellness company, announced continued momentum for its flagship brand FOCUSfactor® following several key milestones and retail expansions across North America, UK, UAE, Turkey and Latin America.
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.
The session on Monday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
MILAN and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology, today announced that it has entered into a securities purchase agreement with institutional investors to purchase 4,285,715 American Depositary Shares ("ADSs") at an offering price of $3.50 per ADS, for gross proceeds of approximately $15.0 million, before deducting placement agent fees and other estimated offering expenses. All of the securities in the offering were sold by Genenta, and no warrants or other derivative securities were issued in connection with this offering.
